ReviewCureus2026
Diffuse Alveolar Hemorrhage in Systemic Lupus Erythematosus: An Updated Clinical Perspective on a High-Mortality Complication.
Review in Cureus, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Diffuse alveolar hemorrhage (DAH) is a rare but devastating complication of systemic lupus erythematosus (SLE), often presenting with acute respiratory failure and carrying high mortality. Clinical recognition is challenging, as hemoptysis may be absent, and early features can overlap with infection or other causes of acute respiratory distress syndrome (ARDS). Diagnosis relies on a high index of suspicion, supported by imaging and bronchoalveolar lavage, while promptly excluding infectious etiologies. Antineutrophil cytoplasmic antibodies (ANCA)-associated vasculitis remains the most important differential diagnosis. Management is largely based on observational data and requires early, aggressive immunosuppression with high-dose glucocorticoids and additional agents such as cyclophosphamide or rituximab. In refractory cases, adjunctive therapies and extracorporeal membrane oxygenation (ECMO) may be lifesaving. Despite therapeutic advances, outcomes remain poor, underscoring the need for early recognition and timely intervention.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.